Klipp från EFNs Börslunch där Vator Securities VD Homan Panahi pratar om det svenska life science-undret och betydelsen för framväxten av nya framgångsrika life science-bolag i Sverige. Se programmet här.
Vator Securities advises Visiopharm on a DKK100 million private placement
ATP, the Danish Growth Fund and the C. L. David Foundation and Collection are among the new investors. The increased capital commitment is an essential part of the company’s growth strategy within the field of tissue diagnostics- and research software for cancer.
Läs mer
Vator Securities Sole Bookrunner in Nanoform SEK 71 million private placement
The private placement was directed to Swedish and Finnish, HNWI, family offices and institutional investors where Mandatum Life Insurance Company (Sampo Group) acted as anchor investor.
Läs mer
Vator Securities advises AlzeCure Pharma on SEK 40 million directed share issue
Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 40 million.
Läs mer
Sole Bookrunner in the largest ever direct share issue in a diagnostics company in Sweden
Vator Securities Sole Bookrunner in successful SEK 324 million direct share issue in Immunovia, the largest ever in a diagnostics company in Sweden
Läs mer
71 MSEK | Q2 2018
40 MSEK | Q2 2018
324 MSEK | Q2 2018
50 MSEK | Q2 2018
60 MSEK | Q1 2018
80 MSEK | Q4 2017
334 MSEK | Q4 2017
90,1 MSEK | Q3 2017
70 MSEK | Q2 2017
